May 27, 2017 3:26 AM ET

Biotechnology

Company Overview of Plandaí Biotechnology, Inc.

Company Overview

Plandaí Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, Artemisia, and cannabis. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. Plandaí Biotechnology, Inc. is based in London, the United Kingdom.

17 Hanover Square

London,  W1S 1BN

United Kingdom

250 Employees

Phone:

44 91 7900 9829

Key Executives for Plandaí Biotechnology, Inc.

Co-Founder, Chairman and Chief Executive Officer
Age: 73
Total Annual Compensation: $180.0K
President, Chief Operating Officer and Director
Age: 31
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2015.

Plandaí Biotechnology, Inc. Key Developments

Plandaí Biotechnology, Inc. expected to report Q3 2017 results on May 26, 2017. This event was calculated by Capital IQ (Created on May 20, 2017).

Plandaí Biotechnology, Inc. expected to report Q3 2017 results on May 26, 2017. This event was calculated by Capital IQ (Created on May 20, 2017).

Plandai Biotechnology Announces Phytofare to Be Focus of Human Clinical Trial for Type II Diabetes in Mauritius

Plandaí Biotechnology, Inc. announced that its green tea catechin-based Phytofare® will be the active ingredient in a human clinical trial investigating the effectiveness of using Phytofare® to regulate blood glucose levels in Type II diabetics. The trial, sponsored by Plandaí's licensee, ProText Mobility, Inc., will be conducted by the Centre International de Developpment Pharmaceutique (CIDP) in the country of Mauritius. Mauritius was selected as the site for the human clinical trial because an estimated 25% of the population suffers from Type II Diabetes. The study is titled "Clinical Trial on Humans to determine the efficacy of Phytofare® for lowering HbA1C levels in II Diabetes patients." When glucose builds up in a person's blood, it binds to the hemoglobin in red blood cells. The HbA1C test measures how much glucose is bound over a 2-3 month period to determine average plasma glucose concentration. The objective of the study is to determine the efficacy of Phytofare® Catechin Complex for improving the levels of hypoglycemia in people with diabetes as emphasized in the American Diabetes Association's new 2017 Standards of Medical Care in Diabetes. Prior to commencing the clinical trial, Plandaí will first be conducting a bioavailability study this month with Mauritian-based CIC Cynologies to determine the human clinical study dosage of Phytofare® Catechin Complex. Results from this bioavailability study are anticipated in June 2017, and can then be used to finish the Type-II diabetes human clinical trial protocol. That study, to be undertaken by CIDP, will commence towards the end of 2017 in Mauritius and will run over a 180-day period. Results will be available soon thereafter. Independent research has indicated that green tea catechins are effective in blocking adipocyte differentiation and proliferation; however, results have not been replicated in human trials because of green tea's poor oral bioavailability*. The Company believes that Phytofare® Catechin Complex because could produce positive results because the unique manufacturing process of Phytofare® yields an end product that contains all eight catechins (antioxidants) found in green tea, and prior human clinical studies have shown that Phytofare® delivers ten times more catechins to the blood plasma over generic catechin extracts, where they remain at therapeutic levels for more than 24 hours.

Plandai Biotechnology Executes Exclusive Distribution Agreement with Cambridge Commodoties for UK and All of Europe

Plandaí Biotechnology, Inc. announced that it has executed an agreement with Cambridge Commodities Ltd. to become the exclusive Phytofare® distributor for the United Kingdom and all of Europe. Based in England, Cambridge Commodities specializes in supplying nutritional ingredients and finished products to the sports nutrition, health and well-being, pet and equine, and food industries. Under the terms of the agreement, Cambridge Commodities will be required to meet specific quarterly sales goals to retain its exclusive distributor status with the initial quotas being established after a short ramp-up period. Cambridge Commodities requires all suppliers to complete a verification process consisting of a meticulous questionnaire and thorough sampling of the material before approval. Their technical team, which includes nine professional lead auditors, travel to all parts of the world to ensure products meet all regulatory and quality requirements, and that those products adhere to environmental and social responsibility policies.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 27, 2017
Cannabis Biosciences Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Plandaí Biotechnology, Inc., please visit www.plandaibiotech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.